Caveolin-1 expression is a predictor of recurrence-free survival in pT2NO prostate carcinoma diagnosed in Japanese patients

Cancer

Volumn 97, Issue 5, 2003, Pages 1225-1233

  Satoh, Takefumi ^a,b   Yang, Guang ^a   Egawa, Shin ^b   Addai, Josephine ^a   Frolov, Anna ^a   Kuwao, Sadahito ^b   Timme, Terry L ^a   Baba, Shiro ^b   Thompson, Timothy C ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adenocarcinoma; Caveolin 1 (cav 1) expression; Prognostic marker; Prostate carcinoma

Indexed keywords

ANTIBODY; CAVEOLIN 1; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGE; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; FOLLOW UP; HAZARD ASSESSMENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INCIDENCE; JAPAN; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; ORGAN DISTRIBUTION; PREDICTION; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; RANK SUM TEST; REGRESSION ANALYSIS; RISK; SCORING SYSTEM; SEMINAL VESICLE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TISSUE SECTION; TREATMENT OUTCOME; TUMOR DIFFERENTIATION;

AGED; CAVEOLIN 1; CAVEOLINS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; ETHNIC GROUPS; HUMANS; IMMUNOHISTOCHEMISTRY; INCIDENCE; JAPAN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0037369151     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11198     Document Type: Article

References (46)

1. Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer. 2000;85:60-67.
2. Pisani P, Bray F, Parkin DM. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer. 2002;97:72-81.
3. Sasagawa I, Nakada T. Epidemiology of prostatic cancer in East Asia. Arch Androl 2001;47:195-201.
4. Nakata S, Takahashi H, Ohtake N, Takei T, Yamanaka H. Trends and characteristics in prostate cancer mortality in Japan. Int J Urol. 2000;7:254-257.
5. Kitagawa T, Tsukuma H, Ajiki K, Oshima A. Prediction of cancer incidence in Japan. Tokyo: Shinohara Shuppan, 1999.
6. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin. 2001;51:15-36.
7. Etzioni R, Legler JM, Feuer EJ, Merrill RM, Cronin KA, Hankey BF. Cancer Surveillance Series: interpreting trends in prostate cancer - Part III: quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. J Natl Cancer Inst. 1999;91: 1033-1039.
8. Feuer EJ, Merrill RM, Hankey BF. Cancer Surveillance Series: interpreting trends in prostate cancer - Part II: cause of death misclassification and the recent rise and fall in prostate cancer mortality. J Natl Cancer Inst. 1999; 91:1025-1032.
9. Hankey BF, Feuer EJ, Clegg LX, et al. Cancer Surveillance Series: interpreting trends in prostate cancer - Part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst. 1999;91:1017-1024.
10. Reynolds T. Prostate cancer: numbers may not tell the whole story. J Natl Cancer Inst. 2000;92:1873-1876.
11. Egawa S, Suyama K, Ohori M, et al. Early detection of prostate cancer. Results of a prostate specific antigen-based detection program in Japan. Cancer. 1995;76:463-472.
12. Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi -institutional update. JAMA. 1997;277:1445-1451.
13. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998;90:766-771.
14. Franks LM. Latent carcinoma of the prostate. J Pathol Bacteriol. 1954;68:603-616.
15. Stamey TA, Ferrari MK, Schmid HP. The value of serial prostate specific antigen determinations 5 years after radio-therapy: steeply increasing values characterize 80% of patients. J Urol. 1993;150:1856-1859.
16. Epstein JI, Carmichael M, Partin AW, Walsh PC. Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup. J Urol. 1993;149:1478-1481.
17. Ohori M, Wheeler TM, Dunn JK, Stamey TA, Scardino PT. The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol. 1994;152(5 Pt 2):1714-1720.
18. Goto Y, Ohori M, Arakawa A, Kattan MW, Wheeler TM, Scardino PT. Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. J Urol. 1996;156:1059-1063.
19. Noguchi M, Stamey TA, McNeal JE, Yemoto CM. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers. J Urol. 2000;164:1596-1600.
20. Yang G, Truong LD, Timme TL, et al. Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res. 1998;4:1873-1880.
21. Parton RG. Caveolae and caveolins. Curr Opin Cell Biol. 1996;8:542-548.
22. Shaul PW, Anderson RG. Role of plasmalemmal caveolae in signal transduction. Am J Physiol. 1998;275(5 Pt 1):L843-L851.
23. Nasu Y, Timme TL, Yang G, et al. Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells. Nat Med. 1998;4:1062-1064.
24. Li L, Yang G, Ebara S, et al. Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells. Cancer Res. 2001;61: 4386-4392.
25. Timme TL, Goltsov A, Tahir S, et al. Caveolin-1 is regulated by c-myc and suppresses c-myc-induced apoptosis. Oncogene. 2000;19:3256-3265.
26. Tahir SA, Yang G, Ebara S, et al. Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res. 2001;61:3882-3885.
27. Thompson T, Timme T, Li L, Goltsov A, Yang G. Caveolin-1: a complex and provocative therapeutic target in prostate cancer and potentially other malignancies. Emerging Therapeutic Targets. 1999;3:337-346.
28. Thompson TC. Metastasis-related genes in prostate cancer: the role of caveolin-1. Cancer Metastasis Rev. 1998;17:439-442.
29. Yang G, Truong LD, Wheeler TM, Thompson TC. Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. Cancer Res. 1999;59:5719-5723.
30. Yang G, Addai J, Ittmann M, Wheeler TM, Thompson TC. Elevated caveolin-1 levels in African-American versus white-American prostate cancer. Clin Cancer Res. 2000;6:3430-3433.
31. Schroder FH, Hermanek P, Denis L, Fair WR, Gospodarowicz MK, Pavone-Macaluso M. The TNM classification of prostate cancer. Prostate. 1992;(Suppl 4):129-138.
32. Machida T, Ohishi Y, Wada T, et al. Clinical evaluation of a new kit (IMX PA Dainapack) for detection of serum prostate specific antigen [in Japanese]. Hinyokika Kiyo. 1993;39:977-984.
33. Klee GG, Dodge LA, Zincke H, Oesterling JE. Measurement of serum prostate specific antigen using IMx prostate specific antigen assay. J Urol. 1994;151:94-98.
34. Arai T, Tsukada T, Nakayama T. Evaluation of AxSYM automated immunoassay analyzer system for determining prostate-specific antigen, and comparison of reactivities for the antigen and diagnostic values of several commercial kits. J Med Pharm Sci. 1994;32:125-136.
35. Egawa S, Koh H, Satoh T, et al. Preoperative serum prostate-specific antigen, clinical stage and Gleason sum as basis for predicting final pathological stage in Japanese patients with prostate cancer. Jpn J Clin Oncol. 1996;26:438-444.
36. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
37. Cox DR. Regression models and life tables. J R Stat Soc. 1972;B34:187-220.
38. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995;273:548-552.
39. Satoh T, Egawa S, Ohori M, et al. Histological characteristics and clinical significance of Japanese prostate cancer with low levels of prostate specific antigen of 4.0 ng/ml or lower. Jpn J Urol. 1999;90:429-435.
40. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA. 1997;277: 1452-1455.
41. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res. 1991;51:222-226.
42. Catalona WJ, Smith DS, Wolfert RL, et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA. 1995; 274:1214-1220.
43. Egawa S, Soh S, Ohori M, et al. The ratio of free to total serum prostate specific antigen and its use in differential diagnosis of prostate carcinoma in Japan. Cancer. 1997;79: 90-98.
44. Brawer MK, Meyer GE, Letran JL, et al. Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology. 1998;52:372-378.
45. Blute ML, Bostwick DG, Bergstralh EJ, et al. Anatomic site-specific positive margins in organ-confined prostate cancer and its impact on outcome after radical prostatectomy. Urology. 1997;50:733-739.
46. Ohori M, Wheeler TM, Kattan MW, Goto Y, Scardino PT. Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol. 1995;154:1818-1824.